REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regenxbio (RGNX) Tops Q4 EPS by 45c, Revenues Beat
February 27, 2019 4:24 PM ESTRegenxbio (NASDAQ: RGNX) reported Q4 EPS of $0.11, $0.45 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $40.78 million versus the consensus estimate of $17.33 million.
Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMDCompleted dosing of six additional subjects in the fourth cohort for a total of 12 subjects; 30 subjects dosed across four cohorts in the trialOn-track to initiate Phase IIb trial for wet AMD in late 2019Continues to advance development of RGX-314 for other chronic retinal diseases; new IND submission for... More